Preventive Health Awareness Fuelling Market Expansion
Large chains are accelerating expansion into Tier-II, III and IV markets, where increasing incomes, an ageing population, and expanding healthcare infrastructure are expected to drive uptake of diagnostic services.
Greater awareness around preventive healthcare and a rising preference for specialised wellness packages are reshaping demand patterns. Despite nearly 60% of the population residing in rural areas, urban markets still generate over 70% of diagnostic revenue.
Volume Growth, Not Pricing, Driving Sector Performance
The report indicates that sectoral revenue growth is being powered by a 12% CAGR in patient volumes and a 17% CAGR in overall test samples. Competitive pressures have kept pricing subdued.
Average revenue per patient declined from ₹786 in FY21 to ₹759 in FY25, and per-test realisations reduced from ₹233 to ₹187 during the same period.
CareEdge expects pricing to remain stable, rising only 1–2% annually, making operational efficiency and scale crucial for sustaining profitability. Competitive Intensity Reshaping Market Structurendia’s diagnostics landscape remains highly fragmented, dominated by standalone labs and regional centres. Organised chains currently represent 20–25% of the market.
With the entry of pharma majors, hospital-backed chains, and e-pharmacy platforms, competition has intensified. CareEdge expects faster consolidation, as national players expand aggressively and smaller labs face sustained margin pressure.
Genomic Diagnostics Emerging as a High-Growth Segment
Genomic testing—used in oncology, prenatal screening, personalised therapy and drug-response prediction—is rapidly becoming a major growth engine. Leading chains are investing in advanced sequencing platforms, specialised genomic labs and highly skilled scientific teams. However, the segment demands significant capital investment, sophisticated software and specialised talent, creating natural entry barriers for smaller and single-location labs.
The diagnostics industry is expected to benefit from rising preventive and wellness testing, increasing chronic disease detection, growing insurance adoption and deeper penetration into emerging markets beyond metros. CareEdge notes that players prioritising volume growth, digital integration, home-collection networks, and genomics will be best positioned for long-term expansion.
